/

BioMarin Pharmaceutical Inc.

BMRN US

BMRN USBioMarin Pharmaceutical Inc.

United States Composite

91.20

USD

-0.86

(-0.93%)

0.87EPS Dil.

102.18P/E

17.20BMarket Cap

BioMarin Pharmaceutical Inc.

BMRN

(United States Composite)

Recent

price

91.20

P/E

ratio

102.18

div

yld

- -

ROIC.AI

Legends:

Stock price

0.29

Beta (1.0 Market)

% total return 04/25

Stock

S&P500

YTD

-9.20

- -

10.22

- -

1.72

- -

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

3.00

3.24

3.65

3.94

4.16

3.98

5.12

5.56

6.73

7.53

8.42

9.52

10.29

10.10

11.31

12.88

0.31

0.00

2.00

-0.48

-0.95

-1.28

-0.92

-1.07

-3.80

-0.67

-0.44

-0.13

4.72

-0.35

0.76

0.89

-0.66

-0.02

-0.30

-1.21

-0.22

-0.89

-1.28

-2.79

-2.27

-1.19

-0.70

-0.64

-0.29

1.01

0.24

0.27

- -

-5.77

-5.71

-3.35

-3.70

-4.29

-4.99

-5.70

-6.32

-8.81

-9.31

-9.50

-9.57

-4.74

-5.06

-4.24

-3.29

2.48

2.55

5.06

4.71

6.37

7.83

8.83

9.41

11.67

11.91

12.79

13.73

19.22

20.01

21.84

23.65

100

103

112

120

138

146

160

166

174

177

179

181

183

185

188

296

325

376

441

501

548

749

890

1,117

1,314

1,491

1,704

1,860

1,846

2,096

2,419

13.41

5.06

0.14

-7.68

-22.01

-28.27

-21.41

-31.63

-18.29

-10.63

-10.40

-6.15

-4.94

-4.03

2.19

6.54

6.53

105

108

102

104

206

-54

-114

-176

-134

-172

-630

-117

-77

-24

854

-64

142

168

7.76

186.22

- -

5.36

11.09

10.40

-0.15

54.70

-12.20

-22.84

-32.15

-17.88

-19.31

-56.43

-8.91

-5.18

-1.40

45.90

-3.47

6.75

6.93

608

390

420

376

573

954

1,162

644

982

1,391

1,533

1,010

1,850

1,728

2,163

1,779

497

378

348

325

656

643

662

661

814

830

486

1,075

1,079

1,083

593

277

322

717

773

1,016

1,341

1,528

2,401

2,766

2,809

2,968

3,122

4,106

4,266

4,603

4,952

4.78

-1.70

- -

0.79

2.39

-81.83

28.53

- -

67.39

46.88

- -

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

503

LT Borrowings

1,085

593

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

188

189

Market Capitalization

16,309

16,664

18,185

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

2,950

2,955

2,956

Cash, Cash Equivalents & STI

1,171

1,126

1,074

Accounts Receivable, Net

610

572

634

Inventories

976

1,032

1,107

Total Current Liabilities

597

1,163

1,177

Payables & Accruals

446

475

435

ST Debt

503

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

16.38%

10.33%

15.41%

Net Income, GAAP

-415.57%

-800.11%

18.31%

Free Cash Flow

-54.19%

-90.35%

18.18%

Total Cash Common Dividend

- -

Total Equity

14.96%

11.22%

7.58%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

486

502

409

450

1,846

2022

519

534

505

538

2,096

2023

596

595

581

646

2,419

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.10

0.07

-0.20

-0.32

-0.35

2022

0.66

0.15

-0.04

0.00

0.76

2023

0.27

0.30

0.21

0.11

0.89

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Business: BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Company News

Yahoo
23 days ago
Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ...
Zacks
a month ago
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Yahoo
a month ago
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Zacks
a month ago
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Tipranks
a month ago
Buy Rating Justified by Voxzogo’s Efficacy in Hypochondroplasia Treatment: A Deep Dive into BioMarin Pharmaceutical’s Clinical Data
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)
Yahoo
a month ago
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Yahoo
a month ago
BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth
Tipranks
2 months ago
Wells Fargo Remains a Buy on BioMarin Pharmaceutical (BMRN)
Yahoo
2 months ago
Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ...
Yahoo
2 months ago
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
Tipranks
2 months ago
BioMarin Pharmaceutical (BMRN) Gets a Buy from TD Cowen

Company News

Yahoo
23 days ago
Insider Sell: EVP, Chief Legal Officer George Davis Sells 24,602 Shares of Biomarin ...
Zacks
a month ago
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Yahoo
a month ago
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
Zacks
a month ago
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
Tipranks
a month ago
Buy Rating Justified by Voxzogo’s Efficacy in Hypochondroplasia Treatment: A Deep Dive into BioMarin Pharmaceutical’s Clinical Data
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)
Yahoo
a month ago
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
Yahoo
a month ago
BioMarin Pharmaceutical: Pioneering Innovations Are Driving Future Growth
Tipranks
2 months ago
Wells Fargo Remains a Buy on BioMarin Pharmaceutical (BMRN)
Yahoo
2 months ago
Insider Sell: President, Worldwide R&D Henry Fuchs Sells 35,341 Shares of Biomarin ...
Yahoo
2 months ago
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
Tipranks
2 months ago
BioMarin Pharmaceutical (BMRN) Gets a Buy from TD Cowen

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

3.00

3.24

3.65

3.94

4.16

3.98

5.12

5.56

6.73

7.53

8.42

9.52

10.29

10.10

11.31

12.88

0.31

0.00

2.00

-0.48

-0.95

-1.28

-0.92

-1.07

-3.80

-0.67

-0.44

-0.13

4.72

-0.35

0.76

0.89

-0.66

-0.02

-0.30

-1.21

-0.22

-0.89

-1.28

-2.79

-2.27

-1.19

-0.70

-0.64

-0.29

1.01

0.24

0.27

- -

-5.77

-5.71

-3.35

-3.70

-4.29

-4.99

-5.70

-6.32

-8.81

-9.31

-9.50

-9.57

-4.74

-5.06

-4.24

-3.29

2.48

2.55

5.06

4.71

6.37

7.83

8.83

9.41

11.67

11.91

12.79

13.73

19.22

20.01

21.84

23.65

100

103

112

120

138

146

160

166

174

177

179

181

183

185

188

296

325

376

441

501

548

749

890

1,117

1,314

1,491

1,704

1,860

1,846

2,096

2,419

13.41

5.06

0.14

-7.68

-22.01

-28.27

-21.41

-31.63

-18.29

-10.63

-10.40

-6.15

-4.94

-4.03

2.19

6.54

6.53

105

108

102

104

206

-54

-114

-176

-134

-172

-630

-117

-77

-24

854

-64

142

168

7.76

186.22

- -

5.36

11.09

10.40

-0.15

54.70

-12.20

-22.84

-32.15

-17.88

-19.31

-56.43

-8.91

-5.18

-1.40

45.90

-3.47

6.75

6.93

608

390

420

376

573

954

1,162

644

982

1,391

1,533

1,010

1,850

1,728

2,163

1,779

497

378

348

325

656

643

662

661

814

830

486

1,075

1,079

1,083

593

277

322

717

773

1,016

1,341

1,528

2,401

2,766

2,809

2,968

3,122

4,106

4,266

4,603

4,952

4.78

-1.70

- -

0.79

2.39

-81.83

28.53

- -

67.39

46.88

- -